AlloVir(ALVR) - 2025 Q1 - Quarterly Results

Business Highlights • Kalaris is currently enrolling a Phase 1, single ascending dose trial to assess the safety, pharmacokinetics, and preliminary treatment effect of TH103 in nAMD patients. Initial clinical data is expected in the fourth quarter of 2025. • As previously announced, Kalaris completed its merger with AlloVir in March 2025. • As recently announced, Kalaris therapeutics had expanded its Board of Directors with the appointment of Leone Patterson as a director and Chair of the Audit Committee. E ...